Antibiotic Therapy for Helicobacter pylori

Jason Collins, Amira Ali-Ibrahim, Duane T. Smoot

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


H pylori is a genetically diverse organism that can quickly develop resistance to antibiotics. This factor, together with its location in the stomach mucus, makes H pylori a difficult organism to treat. Initial treatment of this bacterium is successful more than 80% of the time, but with growing resistance, initial treatment success rates are falling below 80% in many parts of the United States. It is recommended that, after two unsuccessful attempts to treat H pylori, upper gastrointestinal endoscopy with gastric biopsy for bacterial culture and antimicrobial resistance testing be sought to guide further treatment. In addition to the new antibiotic treatments that are being developed for people with multiresistant strains, several companies are looking at the prospects of a therapeutic H pylori vaccine that would easily treat everyone infected with this bacterium. Therapeutic vaccines are currently being studied in animal models with some success [82,83].

Original languageEnglish (US)
Pages (from-to)1125-1140
Number of pages16
JournalMedical Clinics of North America
Issue number6
StatePublished - Nov 2006
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Antibiotic Therapy for Helicobacter pylori'. Together they form a unique fingerprint.

Cite this